



| Day 1: May 24, 2024 | |
|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7:45 AM | Registration Check-in and Breakfast (Agenda is set in the Central Time Zone) |
| 8:20 AM | Welcome and Conference Goals – Bora Lim, MD (Activity Director) |
| Session 1: Keynote | Introduction/Moderator - Bora Lim, MD |
| 8:30 -9:20 AM | Antibody Drug Conjugates (ADCs) in Breast Cancer Mariana Chavez McGregor, MD, MPH |
| Session 2: IBC Session | – Moderator: Angela Alexander, PhD |
| 9:20 AM | ER Metamorphosis – New Knowledge in Translational Research in ER+ IBC Wendy Woodward, MD, PhD |
| 9:40 AM | Importance of MRD in Aggressive Breast Cancers: IBC – Next Direction Anthony Lucci, MD |
| 10:00 AM | Morning Coffee Break and Networking |
| 10:20 AM | Brain Metastasis and Adjuvant Therapy in IBC Azadeh Nasrazadani, MD, PhD |
| 10:40 AM | Characterizing Molecular Residual Disease After Pathologic Complete Response in IBC Jennifer Chen, MD |
| Session 3: Clinical/Translational Advances in Luminal Breast Cancer | – Moderator: Jason Mouabbi, MD |
| 11:00 AM | Imaging of Invasive Lobular Carcinoma Mira Patel, MD |
| 11:20 AM | New Kids on the Block, SERD, PROTAC, and CERANs Ajit Bisen, MD |
| 11:40 AM | Updates on Lobular Carcinoma – Management and Upcoming Therapies Jason Mouabbi, MD |
| 12:00 PM-1:00 PM | Lunch with Advocates: Panel Discussion (No CE Credit Awarded) Moderator: Abbey Kaler, APRN Panelists: Terry Arnold, IBC Network; Eileen Donovan, ABC Program; and Kelsey Magnuson, ABC Program |
| Session 4: Clinical/Translational Advances in Triple Negative Breast Cancer | – Moderator: Diego Pedroza, PhD |
| 1:00 PM | Interaction of Energy Balance and Anti-Tumor Immunity Jasmine Sukumar, MD, PhD |
| 1:20 PM | Predicting Resistance Mechanisms by Analyzing Pre/Post Therapy Primary TNBC Amanda Rinkenbaugh, PhD |
| 1:40 PM | Treating Hostile Microenvironment to Re-Sensitize TNBC Diego Pedroza, PhD |
| 2:00 PM | Afternoon Coffee Break and Networking |
| Session 5: Noncoding RNA Targeted Approaches Workshop | – Moderator: Chunru Lin, PhD |
| 2:20 PM | The Emerging Targeted Therapy of Noncoding RNAs in Breast Cancer Liuqing Yang, PhD |
| 2:40 PM | Enhancer RNAs As Novel Regulators and Therapeutic Targets for Breast Cancer Wenbo Li, PhD |



| | |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------|
| 2:55 PM | Targeting Noncoding RNAs, Inhibitors, Blockers, Degradators and More Zhi Tan, PhD |
| 3:10 PM | Trainee's Presentation Jian Gao [Postdoctoral Fellow] |
| 3:15 PM | Comprehensive Characterizing Noncoding RNAs Using Large-Scale Omics Data Yuan Liu, PhD |
| 3:20 PM | Breast Cancer Advocate Appreciation Ceremony (No CE Credit Awarded) Chunru Lin, PhD |
| 3:40 PM | Interactive Time (No CE Credit Awarded) |
| Session 6: Advocate Time | |
| 4:00-5:00 PM | Integrative Medicine Program Moderator: Abbey Kaler, APRN |
| 4:00 PM | Integrative Medicine – Overview of Program and Specific Studies Meroe Morse, MD |
| 4:15 PM | Experience with Integrative Medicine Patient Panel: Eileen Donovan; Deborah Horwitz; and Kelsey Magnuson |
| 4:30 PM | Integrative Medicine Program – Wrap Up Meroe Morse, MD |
| 4:45 PM | Q&A |
| 5:00 PM | Welcome Reception: Participants, Faculty, and Exhibitors |
| 6:30 PM | Faculty Dinner |



| Day 2: May 25, 2024 | |
|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| 8:00 AM | Registration Check-In and Breakfast |
| 8:20 AM | Day 2 Welcome and Conference Goals – Chunru Lin, PhD |
| Session 7: Keynote II Introduction/Moderator - Chunru Lin, PhD | |
| 8:30-9:20 AM | Development of Vaccines in Adjuvant/Advanced Breast Cancer Settings Paula Pohlmann, MD |
| Session 8: Local Therapies in Advanced Breast Cancers – Moderator: Rahul Sheth, MD | |
| 9:20 AM | When to Take the Patients with Stage IV Breast Cancer to Surgery Helen Johnson, MD |
| 9:40 AM | Challenges of Organizing Surgeries in ABC Alice Hughes, PA |
| 10:00 AM | Morning Coffee Break and Networking |
| 10:20 AM | Cryoablation: Primary Breast Cancer Lumarie Santiago, MD |
| 10:40 AM | Cryoablation: Distant Sites Rahul Sheth, MD |
| Session 9: LN Metastasis in Breast Cancer – Moderator: Larry Coffey II, MS | |
| 11:00 AM | Tumor Draining Lymph Nodes at the Intersection of Immune Surveillance and Cancer Progression Dennis Jones, PhD |
| 11:40 AM | Integration of Multi-Omics in Care of Advanced Breast Cancer, Introduction of OPTIMAs Bora Lim, MD |
| Noon | Closing Remarks and Adjournment Bora Lim, MD |



**Updates in Advanced Breast Cancer:
Local Management and Other New Perspectives**
5/24/2024 – 5/25/2024
7:45:00 AM - 12:00:00 PM

Target Audience:

Professions: Physician (MD or DO), Nurse - RN, Pharmacist, Physician Associate, Social Worker, Other, Nurse - LVN, Nurse - APRN

Description:

This educational initiative is meticulously crafted to empower oncologists and healthcare providers with the latest insights into the nuanced management of advanced breast cancer, equipping them to seamlessly integrate emerging therapies and cutting-edge techniques into their daily clinical practice. The conference is designed to offer a comprehensive exploration of the ever-evolving landscape of breast cancer, focusing on critical updates and treatment trends/guidelines for triple-negative breast cancer, inflammatory breast cancer, locally advanced breast cancer, and metastatic breast cancer. Our distinguished panel of experts, drawn from both within and beyond MD Anderson, will highlight the imperative of adopting a multidisciplinary team approach. Emphasis will be placed on developing strategies for the identification of specific genomic and proteomic signatures associated with breast cancer. Through in-depth discussions and analysis of clinical scenarios, attendees will gain practical insights into delivering a high level of patient-focused, multidisciplinary care, setting the standard for breast cancer patient management. Moreover, our experts will shed light on ongoing clinical trials that present novel therapeutic avenues for advanced, rare, and aggressive forms of breast cancer. The ultimate objective is to equip physicians with the necessary tools to enhance diagnostic precision, tailor therapeutic approaches to the unique characteristics of breast cancer, assess the effectiveness of advanced breast cancer treatments, and make informed referrals to clinical trials when appropriate. By participating in this conference, healthcare providers will not only stay abreast of the latest advancements but will also cultivate the skills needed to navigate the complex landscape of breast cancer care. This knowledge is pivotal for making informed decisions that positively impact patient outcomes and contribute to the ongoing advancement of breast cancer treatment strategies.

Learning Objectives:

- 1 Deliver appropriate therapy utilizing a multidisciplinary care approach to optimize patient outcomes.
- 2 Apply the updated management of locally advanced, recurrent breast cancer.
- 3 Facilitate patient referrals to suitable clinical trials, ensuring alignment with the most current and innovative therapeutic approaches.
- 4 Integrate updated knowledge on new biological findings and genomic information into the clinical translation process, enhancing their ability to provide personalized and evidence-based care in their practice.

Type of Activity: Application-Based (A)

Requirements for Successful Activity Completion:

To successfully complete this activity and be awarded continuing education credit, the following requirements must be met:

- View the recording of the live presentation in its entirety,
- Complete the Pre- and Post-Tests and the active learning assessment(s) contained within the module, and
- Submit the Activity Evaluation, also provided within the module.

Pharmacists must provide their NABP e-Profile ID and date of birth (MMDD).

For other health disciplines, a letter verifying completion of this activity will be provided if requested within 60 days of activity completion: please email your request to PharmacyEducation@mdanderson.org.

Accreditation:

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This application-based activity has been approved for 9.50 contact hour(s) (0.95 CEU) under universal activity number (UAN) UAN JA0004118-0000-24-004-L99-P

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 9.50 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 9.50 Nursing Contact Hour(s)



The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

| | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|----------------------------------------------------------------|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Marcella Sanchez, AA | Other Planning Committee Member | Nothing to disclose - 11/14/2023 |
| Anthony Lucci, MD | Faculty | Nothing to disclose - 04/03/2024 |
| Lumarie Santiago, MD | Faculty | Nothing to disclose - 04/03/2024 |
| Wendy Woodward, MD | Faculty | Nothing to disclose - 10/09/2023 |
| Marian Taylor, DNP, RN, CMSRN | Nurse Planner | Nothing to disclose - 01/19/2024 |
| Miral M Patel, MD | Faculty | Nothing to disclose - 05/19/2024 |
| Rahul Sheth, MD | Faculty | Consulting Fee-Trisalus Grant or research support-Boston Scientific Corporation Consulting Fee-Medtronic, Inc. (any division) Consulting Fee-Replimune Consulting Fee-Varian Medical Systems, Inc - 05/19/2024 |
| Ashton M Underbrink, MPAS, PA-C, Physician assistant-Certified | Other Planning Committee Member | Nothing to disclose - 12/05/2023 |
| Lauren Patterson, PA-C, PA-C | Other Planning Committee Member | Nothing to disclose - 12/12/2023 |
| Abbey J Kaler, MS, MS, APRN, FNP-C, CMSRN | Faculty | Nothing to disclose - 02/29/2024 |
| Ajit K Bisen, MD | Faculty | Advisor-Biotheranostics, Inc (Relationship has ended) Honoraria-Curio Science Workshops (Relationship has ended) Advisor-Novartis |

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

| | | |
|-----------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | Pharmaceuticals Corporation (Relationship has ended) Advisor-Gilead Sciences, Inc. (Relationship has ended) - 03/25/2024 |
| Mary Dev, MSW, LCSW | Other Planning Committee Member | Nothing to disclose - 12/05/2023 |
| Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor | Faculty | Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc. Advisor-Genomic Health, Inc. (Relationship has ended) - 06/27/2023 |
| Alice L Hughes, MPAS | Faculty | Nothing to disclose - 12/12/2023 |
| Jason A Mouabbi, MD | Faculty | Consulting Fee-GE Healthcare Honoraria-Cardinal Health (Relationship has ended) Honoraria-Aptitude Health Honoraria-BostonGene Consulting Fee-AstraZeneca US Honoraria-Gilead Sciences, Inc. Honoraria-Novartis Pharmaceuticals Corporation - 01/12/2024 |
| Angela Alexander, PhD | Faculty | Grant or research support-Merck Sharp & Dohme Corp. (any division) Grant or research support-Daiichi Sankyo, Inc. Grant or research support-Genentech, Inc. - 05/19/2024 |
| Erin Grannan, PharmD, BCOP | Other Planning Committee Member | Nothing to disclose - 12/07/2023 |
| Paula R Pohlmann, MD | Faculty | Grant or research support-Pfizer Inc. Advisor-Pfizer Inc. Grant or research support-Genentech, Inc. (Relationship has ended) Consulting Fee-AbbVie Inc. (Relationship has ended) Consulting Fee-Perthera (Relationship has ended) Consulting Fee-Bolt (Relationship has ended) - 06/09/2023 |
| Azadeh Nasrazadani, MD, PhD | Faculty | Nothing to disclose - 05/19/2024 |
| Terry Arnold | Faculty, Other Planning Committee Member | Nothing to disclose - 12/05/2023 |
| Diego Pedroza, PhD | Faculty | Nothing to disclose - 05/19/2024 |
| Virginia Kirklin, MPH | Other Planning Committee Member | Nothing to disclose - 05/19/2024 |
| Helen M Johnson, MD, IBCLC | Faculty | Nothing to disclose - 05/14/2024 |
| Jasmine Sukumar, MD | Faculty | Nothing to disclose - 03/27/2024 |
| Larry W Coffey II, MS | Faculty | Nothing to disclose - 05/15/2024 |
| Meroe B. Morse, MD | Faculty | Nothing to disclose - 08/23/2023 |
| Chunru Lin, PhD | Co-Director, Faculty | Nothing to disclose - 12/05/2023 |
| Jennifer Chen, MD | Faculty | Nothing to disclose - 05/14/2024 |
| Jian Gao, PhD | Faculty | Nothing to disclose - 05/15/2024 |
| Amanda Rinkenbaugh, PhD | Faculty | Nothing to disclose - 05/19/2024 |
| Bora Lim, MD | Course Director, Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Gilead Sciences, Inc. (Relationship has ended) - 04/04/2024 |
| Dennis Jones, PhD | Faculty | Nothing to disclose - 05/19/2024 |
| Zhi Tan, PhD | Faculty | Nothing to disclose - 05/15/2024 |

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

| | | |
|-------------------|---------|----------------------------------|
| Liuqing Yang, PhD | Faculty | Nothing to disclose - 05/15/2024 |
| Wenbo Li, PhD | Faculty | Nothing to disclose - 05/20/2024 |
| Yuan Liu, PhD | Faculty | Nothing to disclose - 05/21/2024 |
| Kelsey Magnuson | Faculty | Nothing to disclose - 05/21/2024 |
| Deborah Horwitz | Faculty | Nothing to disclose - 05/21/2024 |

REQUIREMENTS FOR SUCCESSFUL ACTIVITY COMPLETION:

To claim CE credits or contact hours for this activity, the participant must:

- **Have a profile in Professional Education Portal (PEP):**
 1. Create an account and complete profile in (PEP).
 2. Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** step in order to log your attendance using the text messaging feature in the future. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333**.
- **Register** for and attend all sessions of this activity.
- **Record Attendance:** During the activity, the learner will TEXT the code: **33506** to **1-844-912-1333**. Learners have up to 24 hours after the activity has ended to text this code in order to record attendance.
- **Evaluation:** Complete the participant evaluation in PEP within 30-days.
- **Claim Credit:** Claim your CE credits. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:

The conference organizing committee wishes to express appreciation to the following company for providing support in part by an educational grant: **Novartis Pharmaceuticals Corporation**

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

EDUCATIONAL GRANT

The conference organizing committee wishes to express appreciation to the following company for providing support in part by an educational grant:

Novartis Pharmaceuticals Corporation

EXHIBITORS

The conference organizing committee wishes to express appreciation to the following companies:

GOLD LEVEL

Novartis

BRONZE LEVEL

AstraZeneca Pharmaceuticals
Gilead Sciences, Inc.
Natera, Inc.

EXHIBITOR LEVEL

Daiichi Sankyo, Inc.
Lilly
Menarini Stemline
Merck